FiercePharmaAsia—Astellas acquisition, Teva’s Celltrion problem, Korea’s digital health initiative

7 years ago

by David Miller

968 Views

Written by David Miller

Astellas pledges $102.5 million for universal donor cell company Universal Cells, approvals of Teva's drugs were delayed by Celltrion's manufacturing problem, Korea plans to gather patient data for a digital health initiative.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!